Monoclonal antibody-based therapy targeting PD1 blockage has brought a transformative shift in the immunotherapeutic strategy against solid tumors. However, the limited effectiveness of this treatment stems from the absence of precise methodologies, such as immunohistochemistry, for identifying patients who could potentially respond well to immune checkpoint inhibitor therapy.
Because a single biomarker is not accurate enough to predict the interaction of the drug at the site of action, we developed a strategy to investigate the complexity of the tumor microenvironment, while also guiding patients towards combination therapy. Using multiplexed high throughput analysis, we have been able to investigate pathways of immune modulation at the molecular level to drug response and resistance.
Download our application note to learn more: